AstraZeneca Pharma India (NSE:ASTRAZEN) EV-to-FCF: (As of Jun. 30, 2026)


NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
93 GF Score
Price ₹8,058.00
GF Value ₹10,870.93
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AstraZeneca Pharma India's Enterprise Value is ₹197,887 Mil. AstraZeneca Pharma India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, AstraZeneca Pharma India's EV-to-FCF for today is .

The historical rank and industry rank for AstraZeneca Pharma India's EV-to-FCF or its related term are showing as below:

NSE:ASTRAZEN' s EV-to-FCF Range Over the Past 10 Years
Min: -1099.2   Med: 0   Max: 0
Current: -1099.2

NSE:ASTRAZEN's EV-to-FCF is ranked worse than
100% of 558 companies
in the Drug Manufacturers industry
Industry Median: 20.045 vs NSE:ASTRAZEN: -1099.20

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-30), AstraZeneca Pharma India's stock price is ₹8058.00. AstraZeneca Pharma India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹75.010. Therefore, AstraZeneca Pharma India's PE Ratio (TTM) for today is 107.43.


AstraZeneca Pharma India  (NSE:ASTRAZEN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AstraZeneca Pharma India's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8058.00/75.010
=107.43

AstraZeneca Pharma India's share price for today is ₹8058.00.
AstraZeneca Pharma India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹75.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


AstraZeneca Pharma India EV-to-FCF Related Terms


AstraZeneca Pharma India EV-to-FCF Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India EV-to-FCF Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.24 153.21 748.10 330.38 -1,016.10

AstraZeneca Pharma India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 330.38 0.00 0.00 0.00 -1,016.10

NSE:ASTRAZEN vs ZTS, UTHR: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Pharma India EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's EV-to-FCF falls into.


NSE:ASTRAZEN
93GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India EV-to-FCF Calculation

AstraZeneca Pharma India's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=197886.750/0
=

AstraZeneca Pharma India's current Enterprise Value is ₹197,887 Mil.
AstraZeneca Pharma India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,058.00 is trading 25.9% below its estimated GF Value™ of ₹10,870.93. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • EV-to-FCF:
  • GF Value™: ₹10,870.93 vs. price of ₹8,058.00 (25.9% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
93GF Score

Get the complete analysis for NSE:ASTRAZEN

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,058.00
Price
₹10,870.93
GF Value